Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
7. EXCLUSIVE: Novation CEO looks back on Medtronic split
In this excerpt from an exclusive MassDevice.com interview with Jody Hatcher, CEO of Novation, the leader of 1 of the largest group purchasing organizations looks back at its much-publicized break up with Medtronic last year.
6. Ortho outlook: Device makers gain as Biomet reports 7% increase in U.S. sales
Fellow orthopedic device makers see Wall Street boosts as market bellwether Biomet forecasts 7% U.S. sales growth and 12% international growth in its preliminary 4th quarter and full-year results.
5. Security report: Software-related recalls growing, FDA unprepared
Medical device security experts call on the FDA to update its surveillance systems to better monitor software issues and track potential problems in privacy and security.
4. Report: Is Medtronic looking to invest in India’s largest med-tech provider?
Reports from India suggest that Medtronic may be negotiating a strategic equity infusion into Trivitron Healthcare, which calls itself the "largest Indian medical technology company."
3. Wall Street flees as Intuitive Surgical reports softness in prostatectomies
Intuitive Surgical shares lose 6% in after-hours trading after the company releases its 2nd quarter earnings report, which beat Wall Street expectations but demonstrated softness in prostatectomy procedures.
2. Device tax will have “unintended consequences”
The 2.3% medical device tax will spur more consolidation within the industry as the measure cuts investments and impacts company valuations, says St. Jude Medical CEO Daniel Starks.
1. St. Jude Medical CEO: The CRM market hasn’t hit bottom yet
Daniel Starks, CEO of St. Jude Medical, says the company has been overly optimistic about the shrinking cardiac rhythm management market.